NO833205L - Fremgangsmaate for modifisering av et virus for vaksineformaal - Google Patents
Fremgangsmaate for modifisering av et virus for vaksineformaalInfo
- Publication number
- NO833205L NO833205L NO833205A NO833205A NO833205L NO 833205 L NO833205 L NO 833205L NO 833205 A NO833205 A NO 833205A NO 833205 A NO833205 A NO 833205A NO 833205 L NO833205 L NO 833205L
- Authority
- NO
- Norway
- Prior art keywords
- virus
- protein
- nucleotide base
- base sequence
- dna
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 28
- 229960005486 vaccine Drugs 0.000 title description 24
- 230000002265 prevention Effects 0.000 title 1
- 241000700605 Viruses Species 0.000 claims description 117
- 108090000623 proteins and genes Proteins 0.000 claims description 117
- 102000004169 proteins and genes Human genes 0.000 claims description 97
- 239000012634 fragment Substances 0.000 claims description 75
- 230000003612 virological effect Effects 0.000 claims description 38
- 241001465754 Metazoa Species 0.000 claims description 33
- 230000028993 immune response Effects 0.000 claims description 25
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 108010067390 Viral Proteins Proteins 0.000 claims description 15
- 108010052285 Membrane Proteins Proteins 0.000 claims description 13
- 102000018697 Membrane Proteins Human genes 0.000 claims description 12
- 230000001717 pathogenic effect Effects 0.000 claims description 12
- 239000013599 cloning vector Substances 0.000 claims description 10
- 239000012678 infectious agent Substances 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 230000035899 viability Effects 0.000 claims description 9
- 241001515965 unidentified phage Species 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 230000008827 biological function Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000001850 reproductive effect Effects 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 73
- 102000053602 DNA Human genes 0.000 description 73
- 239000013612 plasmid Substances 0.000 description 47
- 102000004190 Enzymes Human genes 0.000 description 27
- 108090000790 Enzymes Proteins 0.000 description 27
- 241000701959 Escherichia virus Lambda Species 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 14
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 14
- 241000588724 Escherichia coli Species 0.000 description 13
- 108091008146 restriction endonucleases Proteins 0.000 description 12
- 102000012410 DNA Ligases Human genes 0.000 description 11
- 108010061982 DNA Ligases Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 241000991587 Enterovirus C Species 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 108020005202 Viral DNA Proteins 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 208000000474 Poliomyelitis Diseases 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000003054 hormonal effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000005304 joining Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000004777 protein coat Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000009088 enzymatic function Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- YREOLPGEVLLKMB-UHFFFAOYSA-N 3-methylpyridin-1-ium-2-amine bromide hydrate Chemical group O.[Br-].Cc1ccc[nH+]c1N YREOLPGEVLLKMB-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101710145505 Fiber protein Proteins 0.000 description 2
- 101150082239 G gene Proteins 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000537222 Betabaculovirus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101800001313 Capsid protein VP0 Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101710094396 Hexon protein Proteins 0.000 description 1
- 101710155188 Hexon-interlacing protein Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10341—Use of virus, viral particle or viral elements as a vector
- C12N2795/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/338,416 US4593002A (en) | 1982-01-11 | 1982-01-11 | Viruses with recombinant surface proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO833205L true NO833205L (no) | 1983-09-08 |
Family
ID=23324738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO833205A NO833205L (no) | 1982-01-11 | 1983-09-08 | Fremgangsmaate for modifisering av et virus for vaksineformaal |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4593002A (de) |
| EP (1) | EP0098299B1 (de) |
| JP (1) | JP2593295B2 (de) |
| AU (1) | AU562548B2 (de) |
| CA (1) | CA1211060A (de) |
| DE (1) | DE3367851D1 (de) |
| ES (1) | ES8500322A1 (de) |
| FI (1) | FI833174A0 (de) |
| GB (1) | GB2125065B (de) |
| GR (1) | GR77173B (de) |
| IT (1) | IT1164858B (de) |
| NO (1) | NO833205L (de) |
| NZ (1) | NZ202954A (de) |
| PT (1) | PT76079B (de) |
| WO (1) | WO1983002393A1 (de) |
| ZA (1) | ZA8358B (de) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0117767A1 (de) * | 1983-01-07 | 1984-09-05 | Mgi Pharma, Inc. | Herstellung von Untereinheiten von Parvovirus-Vakzinen |
| IL70704A0 (en) * | 1983-01-19 | 1984-04-30 | Amgen | Methods and materials for development of parvovirus vaccines |
| US5338674A (en) * | 1983-02-25 | 1994-08-16 | Wright Stephen E | Process for producing a vaccine for a pathogenic RNA virus and product thereof |
| NZ209308A (en) * | 1983-08-30 | 1991-08-27 | Genentech Inc | Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein |
| US7264817B1 (en) | 1983-08-30 | 2007-09-04 | Genentech, Inc. | Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it |
| US5288641A (en) * | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| CA1282721C (en) * | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
| US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| US5643579A (en) * | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
| IL76751A (en) * | 1984-11-01 | 1991-04-15 | American Home Prod | Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies |
| FR2573436B1 (fr) * | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
| US6696420B1 (en) | 1984-11-20 | 2004-02-24 | Institut Pasteur | Adenoviral vector with a deletion in the E1A coding region expressing a hetorologous protein |
| IL78775A (en) * | 1985-05-15 | 1992-06-21 | Biotech Australia Pty Ltd | Oral vaccines |
| IL79880A0 (en) * | 1985-08-29 | 1986-11-30 | Inst Medical W & E Hall | Recombinant virus |
| US5763269A (en) * | 1985-09-06 | 1998-06-09 | Syntro Corporation | Recombinant infectious bovine rhinotrocheitis virus |
| US5310668A (en) * | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
| DE3632038A1 (de) * | 1986-09-20 | 1988-03-31 | Behringwerke Ag | Gewebespezifische virale vektoren auf basis des lpv und ihre verwendung |
| NZ219515A (en) | 1987-02-10 | 1989-09-27 | Wellcome Found | Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope |
| EP0349578B2 (de) * | 1987-03-02 | 1998-10-28 | Enzon Labs Inc. | Organismus als Träger für "Single Chain Antibody Domain (SCAD)". |
| DE3854190T2 (de) * | 1987-07-27 | 1996-03-28 | Syntro Corp | Attenuierte herpesviren, herpesviren, die für eine aminosäuresequenz kodierende fremde dns beeinhalten und sie enthaltende impfstoffe. |
| FR2619012B1 (fr) * | 1987-08-07 | 1989-12-22 | Pasteur Institut | Vaccins dont l'epitope caracteristique est incorpore dans une proteine de picornavirus, notamment de poliovirus |
| US5182211A (en) * | 1987-08-07 | 1993-01-26 | Institut Pasteur | Plasmid vectors encoding a protein of a picornavirus |
| US6054566A (en) * | 1988-02-26 | 2000-04-25 | Biosource Technologies, Inc. | Recombinant animal viral nucleic acids |
| US6284492B1 (en) | 1988-02-26 | 2001-09-04 | Large Scale Biology Corporation | Recombinant animal viral nucleic acids |
| US5316931A (en) * | 1988-02-26 | 1994-05-31 | Biosource Genetics Corp. | Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes |
| US20030150019A1 (en) * | 1988-02-26 | 2003-08-07 | Large Scale Biology Corporation | Monopartite RNA virus transformation vectors |
| US5037743A (en) * | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| ES2179854T3 (es) * | 1988-12-13 | 2003-02-01 | Harvard College | Materiales aislados de felv prototipos para uso en modelos de enfermedades y vacunas. |
| US5691170A (en) * | 1989-04-18 | 1997-11-25 | Therion Biologics | Generation of hybrid genes and proteins by virus-mediated recombination |
| US7413537B2 (en) * | 1989-09-01 | 2008-08-19 | Dyax Corp. | Directed evolution of disulfide-bonded micro-proteins |
| EP1132471A3 (de) | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US20030064480A1 (en) * | 1990-06-28 | 2003-04-03 | Leander Lauffer | Fusion proteins with immunoglobulin portions, the preparation and use thereof |
| US7063943B1 (en) | 1990-07-10 | 2006-06-20 | Cambridge Antibody Technology | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6916605B1 (en) | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| WO1992006191A1 (en) * | 1990-09-28 | 1992-04-16 | Protein Engineering Corporation | Proteinaceous anti-dental plaque agents |
| WO1992009690A2 (en) * | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5989886A (en) * | 1991-01-02 | 1999-11-23 | The Johns Hopkins University | Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme |
| DK1279731T3 (da) | 1991-03-01 | 2007-09-24 | Dyax Corp | Fremgangsmåde til udvikling af bindende miniproteiner |
| GB9108386D0 (en) | 1991-04-19 | 1991-06-05 | Agricultural Genetics Co | Modified plant viruses as vectors |
| WO1993000103A1 (en) * | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
| WO1993002202A1 (en) * | 1991-07-19 | 1993-02-04 | Syngene, Inc. | Compositions and methods for reproducing positive diagnostic indications |
| US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5733731A (en) * | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
| ES2313867T3 (es) * | 1991-12-02 | 2009-03-16 | Medical Research Council | Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos. |
| US6511845B1 (en) | 1992-08-07 | 2003-01-28 | Alan R. Davis | Methods for producing an immune response against HIV-1 |
| US5922857A (en) * | 1992-09-28 | 1999-07-13 | Chiron Corporation | Methods and compositions for controlling translation of HCV proteins |
| US5633234A (en) * | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
| US6296852B1 (en) | 1993-04-14 | 2001-10-02 | Commonwealth Scientific And Industrial Research Organisation | Recombinant avian adenovirus vector |
| DE69435081T2 (de) * | 1993-04-14 | 2008-06-12 | Commonwealth Scientific And Industrial Research Organisation | Rekombinanter adenovirusvektor für geflügel |
| AU676042B2 (en) * | 1993-04-14 | 1997-02-27 | Commonwealth Scientific And Industrial Research Organisation | Recombinant avian adenovirus vector |
| US6010861A (en) * | 1994-08-03 | 2000-01-04 | Dgi Biotechnologies, Llc | Target specific screens and their use for discovering small organic molecular pharmacophores |
| US5962311A (en) * | 1994-09-08 | 1999-10-05 | Genvec, Inc. | Short-shafted adenoviral fiber and its use |
| US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5965541A (en) * | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US6465253B1 (en) * | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| EP0787193A1 (de) | 1994-10-18 | 1997-08-06 | Scottish Crop Research Institute | Verfahren zur herstellung von einem chimaren protein |
| US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| DK0833934T4 (da) * | 1995-06-15 | 2012-11-19 | Crucell Holland Bv | Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi |
| US6083693A (en) | 1996-06-14 | 2000-07-04 | Curagen Corporation | Identification and comparison of protein-protein interactions that occur in populations |
| WO1999055365A1 (en) | 1998-04-30 | 1999-11-04 | Cornell Research Foundation, Inc. | Adenoviral vectors with tandem fiber proteins |
| US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| US20040043489A1 (en) * | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
| JP2002525065A (ja) | 1998-09-11 | 2002-08-13 | ジェンベク、インコーポレイティッド | 選択的にターゲッティングされるアデノウイルス |
| US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| EP1157999A1 (de) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen |
| EP1301612A2 (de) * | 2000-05-31 | 2003-04-16 | Genvec, Inc. | Verfahren und zusammenfassung zur zielrichtung von adenoviralen vektoren |
| WO2002024730A2 (en) * | 2000-09-20 | 2002-03-28 | Crucell Holland B.V. | Transduction of dendritic cells using adenoviral vectors |
| US7235233B2 (en) * | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
| ES2376454T3 (es) * | 2000-12-22 | 2012-03-14 | Grad, Carole, Legal Representative Of Howard, Kaplan | Librer�?as de expresión en fago de fragmentos vh humanos. |
| US20030113714A1 (en) * | 2001-09-28 | 2003-06-19 | Belcher Angela M. | Biological control of nanoparticles |
| US20030148380A1 (en) * | 2001-06-05 | 2003-08-07 | Belcher Angela M. | Molecular recognition of materials |
| US20050164515A9 (en) * | 2001-06-05 | 2005-07-28 | Belcher Angela M. | Biological control of nanoparticle nucleation, shape and crystal phase |
| US20030073104A1 (en) * | 2001-10-02 | 2003-04-17 | Belcher Angela M. | Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus |
| ES2335657T3 (es) * | 2002-04-25 | 2010-03-31 | Crucell Holland B.V. | Medios y metodos para la produccion de vectores de adenovirus. |
| US20050064508A1 (en) * | 2003-09-22 | 2005-03-24 | Semzyme | Peptide mediated synthesis of metallic and magnetic materials |
| WO2004089310A2 (en) * | 2003-03-31 | 2004-10-21 | The Board Of Regents Of The University Of Texas System | High-throughput assay for virus entry and drug screening |
| WO2009014782A2 (en) * | 2007-04-27 | 2009-01-29 | Dow Global Technologies Inc. | Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles |
| US10736928B2 (en) | 2016-01-20 | 2020-08-11 | Richard Brian Murphy, JR. | Pegylated recombinant bacteriophage |
| CA3044074A1 (en) | 2016-11-16 | 2018-05-24 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of allergies |
| CN110799529A (zh) | 2017-04-22 | 2020-02-14 | 免疫治疗有限公司 | 改良lamp构建物 |
| BR112019023014A2 (pt) | 2017-05-02 | 2020-05-19 | Immunomic Therapeutics Inc | constructos de lamp aperfeiçoados compreendendo antígenos de câncer |
| JP2021523185A (ja) | 2018-05-15 | 2021-09-02 | イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | アレルゲンを含む改善されたｌａｍｐ構築物 |
| CN112533629A (zh) | 2018-06-19 | 2021-03-19 | 阿尔莫生物科技股份有限公司 | 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法 |
| CN114641306A (zh) | 2019-10-18 | 2022-06-17 | 免疫治疗有限公司 | 包含癌抗原的改良lamp构建物 |
| MX2022008772A (es) | 2020-01-14 | 2022-10-07 | Synthekine Inc | Ortologos de il2 y metodos de uso. |
| AU2023254186A1 (en) | 2022-04-10 | 2024-10-17 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2712615A1 (de) * | 1977-03-18 | 1978-09-21 | Max Planck Gesellschaft | Verfahren zur herstellung von filamentoesen phagen als vektor fuer synthetische rekombinate |
| JPS53133684A (en) * | 1977-04-26 | 1978-11-21 | Noda Sangyo Kagaku Kenkyusho | Novel bacteriophage and fabricating same |
| DE2860386D1 (en) * | 1978-01-05 | 1981-03-19 | Bayer Ag | Molding compositions consisting essentially of unsaturated polyesters, method of preparation and application |
| JPS5558096A (en) * | 1978-10-25 | 1980-04-30 | Noda Sangyo Kagaku Kenkyusho | Method of making novel recombined dna |
| JPS5561798A (en) * | 1978-10-30 | 1980-05-09 | Noda Sangyo Kagaku Kenkyusho | Preparation of novel recombination dna |
| FR2442271A1 (fr) * | 1978-11-27 | 1980-06-20 | Pasteur Institut | Vecteur permettant l'insertion d'un gene procaryote ou eucaryote, et l'excretion de la proteine exprimee |
| FR2480779B2 (fr) * | 1979-08-30 | 1986-07-18 | Anvar | Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur |
| US4442205A (en) * | 1981-09-22 | 1984-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | Simian virus recombinant that directs the synthesis of hepatitis B surface antigen |
-
1982
- 1982-01-11 US US06/338,416 patent/US4593002A/en not_active Expired - Lifetime
-
1983
- 1983-01-05 ZA ZA8358A patent/ZA8358B/xx unknown
- 1983-01-06 NZ NZ202954A patent/NZ202954A/en unknown
- 1983-01-07 DE DE8383900590T patent/DE3367851D1/de not_active Expired
- 1983-01-07 JP JP58500629A patent/JP2593295B2/ja not_active Expired - Lifetime
- 1983-01-07 CA CA000419086A patent/CA1211060A/en not_active Expired
- 1983-01-07 GR GR70220A patent/GR77173B/el unknown
- 1983-01-07 WO PCT/US1983/000015 patent/WO1983002393A1/en active IP Right Grant
- 1983-01-07 AU AU11596/83A patent/AU562548B2/en not_active Ceased
- 1983-01-07 GB GB08322556A patent/GB2125065B/en not_active Expired
- 1983-01-07 EP EP83900590A patent/EP0098299B1/de not_active Expired
- 1983-01-10 PT PT76079A patent/PT76079B/pt unknown
- 1983-01-10 ES ES518870A patent/ES8500322A1/es not_active Expired
- 1983-07-10 IT IT47530/83A patent/IT1164858B/it active
- 1983-09-06 FI FI833174A patent/FI833174A0/fi not_active Application Discontinuation
- 1983-09-08 NO NO833205A patent/NO833205L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES518870A0 (es) | 1984-10-01 |
| GR77173B (de) | 1984-09-10 |
| JP2593295B2 (ja) | 1997-03-26 |
| WO1983002393A1 (en) | 1983-07-21 |
| ZA8358B (en) | 1983-10-26 |
| NZ202954A (en) | 1985-08-16 |
| IT8347530A0 (it) | 1983-07-10 |
| GB2125065B (en) | 1985-05-15 |
| CA1211060A (en) | 1986-09-09 |
| PT76079A (en) | 1983-02-01 |
| GB8322556D0 (en) | 1983-09-21 |
| GB2125065A (en) | 1984-02-29 |
| JPS59500042A (ja) | 1984-01-12 |
| IT1164858B (it) | 1987-04-15 |
| FI833174A (fi) | 1983-09-06 |
| EP0098299B1 (de) | 1986-11-26 |
| DE3367851D1 (en) | 1987-01-15 |
| AU1159683A (en) | 1983-07-28 |
| EP0098299A4 (de) | 1984-07-05 |
| FI833174A0 (fi) | 1983-09-06 |
| EP0098299A1 (de) | 1984-01-18 |
| ES8500322A1 (es) | 1984-10-01 |
| US4593002A (en) | 1986-06-03 |
| PT76079B (en) | 1985-11-11 |
| AU562548B2 (en) | 1987-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO833205L (no) | Fremgangsmaate for modifisering av et virus for vaksineformaal | |
| WO2021254327A1 (zh) | 一种包膜替换型病毒载体疫苗及其构建方法 | |
| CN111088283B (zh) | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 | |
| FI110438B (fi) | Menetelmä mutanttiherpesviruksen valmistamiseksi | |
| CN103930551B (zh) | 猴腺病毒和杂合腺病毒载体 | |
| CA2074502C (en) | Vaccines | |
| US5616326A (en) | Recombinant canine adenovirus 2 (CAV-2) | |
| HU230488B1 (hu) | Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására | |
| CZ375296A3 (en) | Polynucleotide and vaccine containing thereof | |
| US7645455B2 (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
| JP2024512575A (ja) | 弱毒化されたレオウイルスベースのワクチン組成物及びその用途 | |
| JPH01500161A (ja) | Ａｉｄｓの原因ウィルスの糖蛋白質、該糖蛋白質の製造方法及びワクチン | |
| AU779076B2 (en) | Conditionally controlled, attenuated HIV vaccine | |
| JPH10501403A (ja) | 抗体−エンベロープ融合タンパク質および野生型エンベロープ融合タンパク質を含むレトロウィルスベクターを用いる細胞型特異的遺伝子移入 | |
| JPH04500312A (ja) | 自己アセンブルド欠損非自己増殖性ウイルス粒子 | |
| JPH02500327A (ja) | マイコバクテリアに対する遺伝子操作ワクチン | |
| JPH03164181A (ja) | 豚コレラウイルスワクチン | |
| JPH05501950A (ja) | 変異株仮性狂犬病ウィルス及びそれを含有するワクチン | |
| JP2000503551A (ja) | ポリオウイルスの複製コンピテント組換えセービンタイプ１菌株 | |
| JPH10507066A (ja) | ニワトリ感染性貧血ウイルスワクチン | |
| EP1171454B1 (de) | Chimäre nukleinsäuren und polypeptide aus lyssavirus | |
| KR102711723B1 (ko) | 약독화된 레오바이러스 기반의 백신 조성물 및 이의 용도 | |
| US5753490A (en) | Recombinant HIV and modified packaging cells and method for treating acquired immune deficiency syndrome | |
| CN117586422A (zh) | 一种鸭坦布苏病毒核酸疫苗及应用 | |
| CN116390751A (zh) | 多价β-冠状病毒疫苗、其设计和用途 |